ContraFect

ContraFect EBITDA Growth YoY

The Year-over-Year EBITDA Growth of ContraFect (CFRXQ) as of Oct 18, 2026 is -23.74 %. In the previous year, Year-over-Year EBITDA Growth was -38.05 % — a change of -37.63% (higher).

EBITDA Growth YoY

-23.74 %

YoY

-37.63%

Last updated:

Year-over-Year EBITDA Growth of ContraFect is 2022 -23.74 % . Year-over-Year EBITDA Growth of ContraFect was 2021 -38.05 % . It decreases by -37.63% higher compared to the previous year.

The ContraFect EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2015
-47.99 USD
Jan 1, 2016
-33.75 USD
Jan 1, 2017
20.79 USD
Jan 1, 2018
-17.17 USD
Jan 1, 2019
10.44 USD
Jan 1, 2020
-22.86 USD
Jan 1, 2021
-38.05 USD
Jan 1, 2022
-23.74 USD
The ContraFect EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-23.74 %-37.63%
-38.05 %+66.50%
-22.86 %-318.86%
10.44 %-160.83%
-17.17 %-182.59%
20.79 %-161.60%
-33.75 %-29.69%
-47.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

Year-over-Year EBITDA Growth of ContraFect is -23.74 % in 2022.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth ContraFect since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's ContraFect historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ContraFect

All Key Metrics — ContraFect